TRIM5 and glioblastoma: Importantly, we found that overexpression and knockdown of CD2AP increased and decreased TRIM5 levels, respectively, and that downregulation of TRIM5 reversed the activated NF-κB signaling in GBM cells with CD2AP overexpression.